Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
<p>Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Global Journal of Cancer Therapy - Peertechz Publications,
2021-02-13.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|